Evaluation of effects of eucalyptus tablets on the process of covid 19 disease

Phase 3

• Conditions: COVID-19 disease.; COVID-19; U07.1

• Registration Number: IRCT20200913048701N1
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 October 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Patients between 40 and 60 years of age with new coronavirus infection 2019 who have been admitted to Firoozabadi Hospital.

Exclusion Criteria

Age over 60 years
Age under 40 years
No hospitalization
No infection with coronavirus 2019

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood oxygen level (SPO2%). Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: Pulse oximeter device.;Inflammatory index CRP. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: blood test.;Cough. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: Qualitative (mild-moderate-severe).;Blood lymphocyte count. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: blood test.;White blood cell count. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: blood test.

Secondary Outcome Measures

Name	Time	Method
The rate of disease progression. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: Researcher checklist.;Duration of hospitalization. Timepoint: Before the intervention and 7 days after the intervention. Method of measurement: Researcher checklist.